[Diflucortolone valerianate (Nerisona) in the treatment of corticoid-sensitive dermatoses in childhood].
The efficacy and tolerance of 0.1% diflucortolone valerate (Nerisona) in cream, ointment and fatty ointment formulations were investigated in a study in which no control preparations were used. The study was conducted in 657 children over a period of three weeks. The results were compared with those of a trial with the same design conducted with 4,878 adults. Our observations were mainly concentrated on the two groups eczema/dermatitis and neurodermatitis (atopic dermatitis). Nearly 90% of the children taking part in the study exhibited these clinical pictures. By far the best therapeutic results were obtained in neurodermatitis. There was only one therapy failure among 198 patients (99.5%). Overall the results obtained in children were markedly better than those recorded for adults.
D000287:Administration, Topical; D000328:Adult; D000367:Age Factors; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003872:Dermatitis / Q000188:drug therapy*; D004341:Drug Evaluation; D004485:Eczema / Q000188:drug therapy; D005448:Fluocortolone / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D009450:Neurodermatitis / Q000188:drug therapy; D009824:Ointments; D011244:Pregnadienediols / Q000627:therapeutic use*
D009824:Ointments; D011244:Pregnadienediols; D005448:Fluocortolone
Diflucortolonvalerianat (Nerisona) bei der Behandlung kortikoidempfindlicher Dermatosen im Kindesalter.